Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
whole virus inactivated influenza H5N1 vaccine (Jiangsu CDC)
- Development stage
- Unknown
- Lead developer
- Jiangsu Provincial Center for Disease Control and Prevention
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The whole virus inactivated influenza H5N1 vaccine, developed by the Jiangsu Province Centers for Disease Control and Prevention, is a monovalent vaccine candidate designed to provide protection against the H5N1 subtype of the Influenza A virus. The vaccine utilizes a whole-virus platform where the H5N1 virus is inactivated (killed), typically through chemical treatment, to eliminate its ability to replicate while maintaining the structural integrity of its surface antigens. Upon intramuscular administration, the vaccine presents the entire viral proteome, including key antigens such as hemagglutinin (HA) and neuraminidase (NA), to the host immune system to stimulate the production of neutralizing antibodies and prime cellular immunity. This candidate has been investigated in Phase I clinical trials to evaluate its safety and immunogenicity across various dose levels (7.5μg, 15.0μg, and 30.0μg) in healthy adolescent and adult populations.
- Other names
- whole virus inactivated influenza H5N1 vaccineH5N1 inactivated vaccineH-5N1 inactivated vaccineH 5N1 inactivated vaccineJiangsu CDC H5N1 vaccine
02
Targets
HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on whole virus inactivated influenza H5N1 vaccine (Jiangsu CDC).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on whole virus inactivated influenza H5N1 vaccine (Jiangsu CDC).